CKD-828 Primary Hypertension Trial(Dose-selection)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 430 participants.

Also called NCT01128322

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 430 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01128322
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01128322. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CKD-828 Primary Hypertension Trial(Dose-selection)
Condition
Hypertension
Intervention (Drug)
S-Amlodipine, Telmisartan
Intervention (Drug)
S-Amlodipine
Intervention (Drug)
Telmisartan
Intervention (Drug)
Placebo
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct01128322
Content hash
082e3fe36428f5ef0729baa98b9ee1617ee4474ed02cffcde9d716ad66ba21df